A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma.

In Escudier et al study, [ 18 ] the intermediate MSKCC risk group showed a trend toward improved PFS for sorafenib (HR, 1.16).Thus, sorafenib may be beneficial for intermediate-risk patients, who constitute the majority of newly diagnosed patients.

also in 53,322 other papers

Moreover, there was a positive trend of PFS that favored sorafenib in patients who had liver metastases (HR, 1.52) and in patients who had bone metastases (HR, 1.17).

also in 11,005 other papers